Array BioPharma, a biopharmaceutical company, has dosed its first type 2 diabetic patient in a Phase I clinical trial with its novel small molecule glucokinase activator, ARRY-403.
In the Phase I trial, the compound will be evaluated in single- and multiple-dose escalation studies in type 2 diabetic patients. The study is designed to evaluate safety, tolerability, exposure and blood glucose control.
In preclinical studies, ARRY-403 demonstrated effective control of both fasting and non-fasting blood glucose concentrations. The glucokinase activator (GKA) activity of ARRY-403 was shown to be highly dependent on blood glucose concentrations, said Array BioPharma.
Kevin Koch, president and chief scientific officer of Array BioPharma, said: There is a significant need for new, more effective oral treatments for Type 2 diabetes – and glucokinase activation represents a promising new mechanism. We believe ARRY-403 will provide diabetic patients with superior glucose control, combined with an improved safety profile.
Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory diseases, pain and metabolic diseases. Proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs.